abstract |
The present invention provides a method for engineering B lymphocytes by utilizing activation-induced cytidine deaminase of the B lymphocyte. Thereby, use of engineered nucleases, such as Cas nuclease, can be avoided. Engineered B cells are useful to produce customized antibodies and for B cell therapy. Accordingly, the present invention also provides engineered B cells and customized antibodies produced by engineered B cells. |